Vertiv Holdings Co Total Cost of Revenue decreased by 6.2% to $1.65B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 22.3%, from $1.35B to $1.65B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 17.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $851.00M | $847.20M | $1.04B | $852.80M | $1.03B | $1.05B | $1.14B | $1.03B | $1.14B | $1.12B | $1.18B | $1.07B | $1.21B | $1.32B | $1.48B | $1.35B | $1.74B | $1.67B | $1.76B | $1.65B |
| QoQ Change | — | -0.4% | +22.4% | -17.7% | +20.5% | +2.3% | +8.7% | -10.3% | +11.2% | -2.2% | +6.0% | -9.2% | +12.9% | +8.7% | +12.1% | -8.6% | +29.0% | -4.4% | +5.6% | -6.2% |
| YoY Change | — | — | — | — | +20.8% | +24.2% | +10.2% | +20.3% | +10.9% | +6.0% | +3.4% | +4.6% | +6.3% | +18.1% | +24.9% | +25.8% | +43.7% | +26.4% | +19.1% | +22.3% |